Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH
BACKGROUND Benign prostatic hyperplasia ( BPH ) , a nonmalignant enlargement of the prostate , can lead to obstructive and irritative lower urinary tract symptoms ( LUTS ) .
The pharmacologic use of plants and herbs ( phytotherapy ) for the treatment of LUTS associated with BPH is common .
The extract of the berry of the American saw palmetto , or dwarf palm plant , Serenoa repens ( also known by its botanical name of Sabal serrulatum ) , is one of several phytotherapeutic agents available for the treatment of BPH .
OBJECTIVES This systematic review aim ed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH .
Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo.
OBJECTIVE The mechanism of action of plant extracts used for the medical treatment of human benign prostatic hyperplasia ( BPH ) is still unknown . In this prospect i ve , r and omized , double-blind trial , we investigated the possible influence of the Sabal serrulata extract IDS 89 ( Strogen ) on epithelial and stromal enzyme activities of BPH tissue . METHODS 18 patients with BPH were r and omly assigned to receive 3 x 2 capsules Strogen uno ( 320 mg/capsule ) ( n = 8) or placebo ( n = 10 ) daily for 3 months . The activity ( Vmax and Km ) of 5 alpha-reductase . 3 alpha-HSORred , 3 beta-HSORred , and creatine kinase was determined in mechanically separated epithelium and stroma of human BPH . RESULTS The multivariate correlation analysis revealed a positive correlation between therapy and the following enzyme alterations : ( 1 ) In epithelium , the substrate affinity of the 5 alpha-reductase decreased slightly ( increase of Km value ) . ( 2 ) In stroma , the Vmax value of the 3 alpha-HSORred increased statistically distinctly , leading to a moderate increase of Vmax/Km . ( 3 ) In stroma , the Vmax value of the 3 beta-HSORred increased moderately , but not statistically significant . ( 4 ) In stroma , the Vmax value of creatine kinase increased significantly , leading to a statistically distinct increase of Vmax/Km . CONCLUSION This double-blind , placebo-controlled clinical trial with the S. serrulata extract IDS 89 revealed significant biochemical changes at the cellular level of BPH tissue . However , the alterations are merely moderate , their biochemical causes and consequences regarding the pathophysiology of BPH rather uncertain . Therefore , more studies are needed before plant extracts like IDS 89 become valid c and i date s likewise synthetic substances already used for medical treatment of human BPH
Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH
BACKGROUND Benign prostatic hyperplasia ( BPH ) , a nonmalignant enlargement of the prostate , can lead to obstructive and irritative lower urinary tract symptoms ( LUTS ) .
The pharmacologic use of plants and herbs ( phytotherapy ) for the treatment of LUTS associated with BPH is common .
The extract of the berry of the American saw palmetto , or dwarf palm plant , Serenoa repens ( also known by its botanical name of Sabal serrulatum ) , is one of several phytotherapeutic agents available for the treatment of BPH .
OBJECTIVES This systematic review aim ed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH .